Cargando…
Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We h...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111528/ https://www.ncbi.nlm.nih.gov/pubmed/33995581 http://dx.doi.org/10.1177/17562848211009716 |
_version_ | 1783690519792058368 |
---|---|
author | Pellat, Anna Deyra, Jacques Husson, Marie Benamouzig, Robert Coriat, Romain Chaussade, Stanislas |
author_facet | Pellat, Anna Deyra, Jacques Husson, Marie Benamouzig, Robert Coriat, Romain Chaussade, Stanislas |
author_sort | Pellat, Anna |
collection | PubMed |
description | BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We herein question this threshold’s relevance in a French population and perform a retrospective observational study using the Parisian database between 1 April 2015 and 31 December 2018. METHODS: Rates of participation, numbers of positive faecal immunological test (FIT), detection rates and positive predictive values for advanced adenomas and/or colorectal cancer were determined. Mean positivity values for colorectal lesions were calculated. RESULTS: In our population, there were 4.1% positive tests and 67.6% colonoscopy results available with final reports. Positive predictive value for advanced adenomas and colorectal cancer were 30% [95% confidence interval (CI) 29.8–30.3] and 7.4% (95% CI 7.35–7.52), respectively. The mean positivity value for all positive tests in our population was 101.7 µg Hb/g of stool (95% CI 85–118.3). There were 1136 normal colonoscopies (21.4%) with a mean positivity value of 88.6 μg Hb/g of stool. Following a negative test in a first screening campaign, 40.8% of patients in our population performed a second test with a positivity rate of 1.3% and with the encounter of 81 colorectal cancers. The risk of having a positive test during the second screening campaign and finding advanced colorectal lesions significantly increased (all p < 0.001) when comparing negative FIT results ranging between 15 and 29 μg Hb/g of stool to 0 and 14 μg Hb/g of stool from the previous campaign. CONCLUSION: Using the current positivity threshold, some patients were considered negative with a delay in colorectal cancer diagnosis, suggesting the threshold could be lowered. Also, the mean positivity value for normal colonoscopies was high, raising the question of upper gastrointestinal bleeding. |
format | Online Article Text |
id | pubmed-8111528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-81115282021-05-13 Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? Pellat, Anna Deyra, Jacques Husson, Marie Benamouzig, Robert Coriat, Romain Chaussade, Stanislas Therap Adv Gastroenterol Original Research BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We herein question this threshold’s relevance in a French population and perform a retrospective observational study using the Parisian database between 1 April 2015 and 31 December 2018. METHODS: Rates of participation, numbers of positive faecal immunological test (FIT), detection rates and positive predictive values for advanced adenomas and/or colorectal cancer were determined. Mean positivity values for colorectal lesions were calculated. RESULTS: In our population, there were 4.1% positive tests and 67.6% colonoscopy results available with final reports. Positive predictive value for advanced adenomas and colorectal cancer were 30% [95% confidence interval (CI) 29.8–30.3] and 7.4% (95% CI 7.35–7.52), respectively. The mean positivity value for all positive tests in our population was 101.7 µg Hb/g of stool (95% CI 85–118.3). There were 1136 normal colonoscopies (21.4%) with a mean positivity value of 88.6 μg Hb/g of stool. Following a negative test in a first screening campaign, 40.8% of patients in our population performed a second test with a positivity rate of 1.3% and with the encounter of 81 colorectal cancers. The risk of having a positive test during the second screening campaign and finding advanced colorectal lesions significantly increased (all p < 0.001) when comparing negative FIT results ranging between 15 and 29 μg Hb/g of stool to 0 and 14 μg Hb/g of stool from the previous campaign. CONCLUSION: Using the current positivity threshold, some patients were considered negative with a delay in colorectal cancer diagnosis, suggesting the threshold could be lowered. Also, the mean positivity value for normal colonoscopies was high, raising the question of upper gastrointestinal bleeding. SAGE Publications 2021-05-07 /pmc/articles/PMC8111528/ /pubmed/33995581 http://dx.doi.org/10.1177/17562848211009716 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Pellat, Anna Deyra, Jacques Husson, Marie Benamouzig, Robert Coriat, Romain Chaussade, Stanislas Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title | Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title_full | Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title_fullStr | Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title_full_unstemmed | Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title_short | Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? |
title_sort | colorectal cancer screening programme: is the french faecal immunological test (fit) threshold optimal? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111528/ https://www.ncbi.nlm.nih.gov/pubmed/33995581 http://dx.doi.org/10.1177/17562848211009716 |
work_keys_str_mv | AT pellatanna colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal AT deyrajacques colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal AT hussonmarie colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal AT benamouzigrobert colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal AT coriatromain colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal AT chaussadestanislas colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal |